Clinical Trial

Blood Cell RNA-Based Cancer Detection

Study acronym: eRBCDet
Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2024 (before its estimated November 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Early diagnosis of cancer may provide patients with more treatment options and hopefully prolong survival. The purpose of this multi-center study is to collect peripheral blood from newly diagnosed cancer patients and healthy donors to establish a blood cell RNA-based model for the differentiation of cancer patients and healthy donors. The area under the receiver operating characteristic (AUROC), sensitivity and specificity of the test in the early detection of multiple cancers will be measured.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05839834
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Neoplasms, Cancer
Enrollment 5,000 participants
Start Date 2021-02-08
Primary Completion 2024-11-01 (estimated)
Study Completion 2024-12-08 (estimated)
Updated on ClinicalTrials.gov 2024-07-24